EBS
Emergent BioSolutions Inc.
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · US
$6.20
−0.56%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 770.2M | 742.9M | 1.0B | 1.0B | 1.1B |
| Cost of Revenue | 389.7M | 392.3M | 668.2M | 689.3M | 644.5M |
| Gross Profit | 380.5M | 350.6M | 375.4M | 360.0M | 473.0M |
| Operating Expenses | |||||
| R&D Expense | 45.3M | 53.8M | 70.7M | 111.4M | 188.3M |
| SG&A Expense | 181.1M | 186.6M | 298.7M | 356.7M | 339.5M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 208.5M | — | 114.7M | 618.3M | 115.2M |
| Total Operating Expenses | 434.9M | 240.4M | 484.1M | 1.1B | 643.0M |
| Cost and Expenses | 824.6M | 632.7M | 1.2B | 1.8B | 1.3B |
| Operating Income (EBIT) | (54.4M) | 110.2M | (108.7M) | (726.4M) | (170.0M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 50.9M | 59.3M | 71.0M | 87.9M | 37.3M |
| Net Interest Income | (50.9M) | (59.3M) | (71.0M) | (87.9M) | (37.3M) |
| Other Non-Op Income/Expense | (91.6M) | (27.4M) | (34.2M) | (4.8M) | (49.0M) |
| Non-Operating Income (excl Interest) | 40.7M | (31.9M) | (56.5M) | (558.3M) | (60.7M) |
| EBT (Pre-Tax Income) | (146.0M) | 82.8M | (142.9M) | (731.2M) | (219.0M) |
| Income Tax Expense | 30.8M | 30.2M | 47.7M | 29.3M | (7.4M) |
| Bottom Line | |||||
| Net Income | (176.8M) | 52.6M | (190.6M) | (760.5M) | (211.6M) |
| Earnings from Cont. Ops | (176.8M) | 52.6M | (190.6M) | (760.5M) | (211.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (176.8M) | 52.6M | (190.6M) | (760.5M) | (211.6M) |
| Per Share | |||||
| Basic EPS | ($3.44) | $0.98 | ($3.60) | ($14.85) | ($4.22) |
| Diluted EPS | ($3.55) | $0.93 | ($3.60) | ($14.85) | ($4.22) |
| Revenue Per Share | $14.93 | $13.89 | $19.69 | $20.49 | $22.31 |
| Shares | |||||
| Basic Shares Outstanding | 51.6M | 53.5M | 53.0M | 51.2M | 50.1M |
| Diluted Shares Outstanding | 51.6M | 56.7M | 53.0M | 51.2M | 50.1M |
| Profitability Metrics | |||||
| EBITDA | (23.7M) | 240.4M | 53.4M | (47.0M) | 15.7M |
| D&A | 71.4M | 98.3M | 105.6M | 121.1M | 125.0M |
| EBIT | (95.1M) | 142.1M | (52.2M) | (168.1M) | (109.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026